# Kowa Pharmaceuticals America, Inc.

> Kowa Pharmaceuticals is a U.S. ophthalmic pharmaceutical company committed to developing and commercializing innovative therapies for eye care, with a focus on glaucoma and vision preservation. Kowa Pharmaceuticals also has a longstanding heritage in cardiometabolic and anti-inflammatory therapeutics.

Kowa Pharmaceuticals America, Inc. is the U.S. subsidiary of Kowa Company, Ltd., a Japanese pharmaceutical and healthcare company with decades of global experience. Kowa Pharmaceuticals America partners with leading ophthalmic research organizations to bring innovative treatments and diagnostic therapies to patients in the United States.

## Pages

- [Home](https://www.kowapharma.com/): Overview of Kowa Pharmaceuticals America, mission, and latest news.
- [About](https://www.kowapharma.com/about): Leadership team and board of directors.
- [Products & Pipeline](https://www.kowapharma.com/products-and-pipeline): Current product portfolio and clinical pipeline, including NCX 470 for glaucoma.
- [Newsroom](https://www.kowapharma.com/newsroom): Press releases and company news.
- [Careers](https://www.kowapharma.com/careers): Open positions across Sales Management, Sales Representative, and Corporate roles.
- [Contact](https://www.kowapharma.com/contact): Contact information for Kowa Pharmaceuticals America.

## Key Focus Areas

- Glaucoma treatment — NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop licensed from Nicox SA, targeting open-angle glaucoma and ocular hypertension. NDA submitted to the FDA in H1 2026; commercial launch expected before end of 2027.
- Ophthalmic drug development and commercialization in the U.S. market.
- Strategic licensing partnerships with international ophthalmology companies.

## Company Information

- Headquarters: Montgomery, Alabama, USA
- Parent company: Kowa Company, Ltd. (Japan)
- Therapeutic focus: Ophthalmology / Eye Care
- Website: https://www.kowapharma.com